Targets › CCND1
3 programs from 3 companies in 61 trials: 33 Phase 2, 20 Phase 1, 8 Phase 3; Oncology, Other; next expected readout Dec 2026.
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1)…. (UniProt, P24385)
Open in Phaseline: the race on CCND1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Palbociclib CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | CCND1, CDK6, CDK4 | Phase 3 | Breast Cancer; Ewing Sarcoma; Breast Cancer Recurrent; Metastatic Breast Cancer … | Dec 2026 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | cisplatin platinum-based chemotherapy agent; forms DNA cross-links | CCND1 | Phase 2 | Neuroendocrine Carcinoma | Jan 2027 |
| Henan Cancer Hospital | Darsilide CDK4/6 inhibitor | CCND1 | Phase 2 | Breast Cancer | Jun 2029 |
Breast Cancer (10) Metastatic Breast Cancer (4) Advanced Lymphoma (2) Head and Neck Squamous Cell Carcinoma (2) Early-Stage Breast Carcinoma (2) Ewing Sarcoma (1) Breast Cancer Recurrent (1) Breast Neoplasm Female (1) HPV-unrelated Head and Neck Squamous Cell Carcinoma (1) HER-2 Positive Breast Cancer (1) Metastatic Breast Carcinoma (1) Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer (1)
small molecule (3)
Pfizer (1) GERCOR - Multidisciplinary Oncology Cooperative Group (1) Henan Cancer Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.